1-4 of 4
Andrew Z Cakana, MD, FRCPath
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Jesús F San Miguel, MD PhD, Rudolf Schlag, MD, Nuriet K Khuageva, MD, Meletios Athanasios Dimopoulos, MD, Ofer Shpilberg, MD, MPH, Martin Kropff, MD, Ivan Spicka, MD, PhD, Maria T Petrucci, Antonio Palumbo, MD, Olga S Samoilova, MD, Anna Dmoszynska, Kudrat M Abdulkadyrov, Prof, Michel Delforge, MD, PhF, Bin Jiang, María-Victoria Mateos, MD, PhD, Kenneth C. Anderson, MD, Dixie-Lee Esseltine, MD, FRCPC, Kevin Liu, PhD, William M Deraedt, PhD, Andrew Z Cakana, MD, FRCPath, Helgi van de Velde, MD, PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2011) 118 (21): 476.
https://doi.org/10.1182/blood.V118.21.476.476
Published: 2011
Journal Articles

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Bertrand Coiffier, MD, Weimin Li, Erin D Henitz, BS, J. D. Karkera, PhD, Reyna Favis, PhD, Dana Gaffney, MS, Alice Shapiro, MS, Panteli Theocharous, BSc (hons), MSc, PhD, Yusri A Elsayed, MD, PhD, Helgi van de Velde, MD, PhD, Evgenii A Osmanov, MD, PhD, Xiaonan Hong, MD, Adriana Scheliga, MD, Fritz C. Offner, MD, PhD, Simon Rule, Adriana C Teixeira, MD, Jan Walewski, MD, PhD, Sven de Vos, MD, PhD, Michael Crump, MD, FRCPC, Ofer Shpilberg, MD, MPH, Pier Luigi Zinzani, MD, PhD, Andrew Z Cakana, MD, FRCPath, Dixie-Lee Esseltine, MD, FRCPC, George Mulligan, PhD, Deborah S Ricci, PhD
Journal: Blood
Blood (2011) 118 (21): 265.
https://doi.org/10.1182/blood.V118.21.265.265
Published: 2011
Journal Articles

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Jesús F San Miguel, MD PhD, Paul G. Richardson, MD, Robert Z. Orlowski, MD, PhD, Hartmut Goldschmidt, Deyanira Corzo, MD, Carol Satler, Dixie-Lee Esseltine, MD, FRCPC, Rachel Neuwirth, MS, Maria Ponsillo, MD, Andrew Z Cakana, MD, FRCPath, Jay King, MD, William M Deraedt, PhD, Avinash Desai, Yana Lutska, Dina Gifkins, PhD, Kevin Liu, PhD, Pieter Sonneveld, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2933.
https://doi.org/10.1182/blood.V118.21.2933.2933
Published: 2011
Journal Articles

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

Philippe Moreau, MD, Ievgenii I Karamanesht, MD, Natalia Domnikova, Maryna Y Kyselyova, MD, Kateryna Vilchevska, Vadim A Doronin, MD, PhD, Alexander Schmidt, MD, Cyrille Hulin, MD, Xavier Leleu, MD, PhD, Dixie-Lee Esseltine, MD, FRCPC, Karthik Venkatakrishnan, Donna M Skee, BS, Huaibao Feng, PhD, Suzette Girgis, Andrew Z Cakana, MD, FRCPath, William M Deraedt, PhD, Thierry Facon, MD
Journal: Blood
Blood (2011) 118 (21): 1863.
https://doi.org/10.1182/blood.V118.21.1863.1863
Published: 2011